Protective effects of diltiazem and ryanodine against ischemia-reperfusion injury in neonatal rabbit hearts.
The effects of diltiazem, a sarcolemmal Ca2+ channel blocker, and ryanodine, an inhibitor of sarcoplasmic reticulum function, were investigated in isolated newborn rabbit hearts (2 to 5 days old) subjected to ischemia and reperfusion. After cardioplegic arrest with St. Thomas' Hospital solution, global ischemia was induced at 37 degrees C (normothermia) for 45 minutes or at 20 degrees C (hypothermia) for 180 minutes. The hearts were then reperfused at 37 degrees C for 30 minutes. Diltiazem or ryanodine, at concentrations that have minimal to moderately negative inotropic effects under nonischemic conditions, was added to the cardioplegic solution. After normothermic ischemia, reperfusion of untreated hearts resulted in recovery of left ventricular developed pressure to 52.9% +/- 2.5% of the preischemic level. In hearts treated with diltiazem, recovery of left ventricular developed pressure was significantly improved (84.2% +/- 2.9% at 3 x 10(-8) mol/L; p < 0.01). Comparable improvement was achieved with ryanodine (90.5% +/- 4.1% at 10(-9) mol/L; p < 0.01). Creatine kinase leakage and structural derangement of mitochondria were also reduced by both agents. With hypothermic ischemia, left ventricular developed pressure recovered in untreated hearts to 72.7% +/- 3.3% of preischemic values. Treatment with diltiazem improved the recovery of left ventricular developed pressure to 96.9% +/- 3.5% at 3 x 10(-8) mol/L and reduced creatine kinase leakage and mitochondrial damage. Ryanodine also improved the recovery of left ventricular developed pressure and attenuated ultrastructural damage. These findings suggest that Ca2+ handling by the sarcoplasmic reticulum, like transsarcolemmal Ca2+ influx, plays an important role in the pathogenesis of myocardial ischemia-reperfusion injury in the neonatal heart despite the morphologic and functional immaturity of the sarcoplasmic reticulum in the neonate.
Akita
T
T
Department of Thoracic Surgery, School of Medicine, Nagoya University, Japan.
Abe
T
T
Kato
S
S
Kodama
I
I
Toyama
J
J
D000818:Animals; D000831:Animals, Newborn; D001639:Bicarbonates; D001794:Blood Pressure; D002122:Calcium Chloride; D002314:Cardioplegic Solutions; D003402:Creatine Kinase / Q000032:analysis; D004110:Diltiazem / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D007036:Hypothermia, Induced; D066298:In Vitro Techniques; D008274:Magnesium; D008854:Microscopy, Electron; D009200:Myocardial Contraction / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D009206:Myocardium / Q000648:ultrastructure; D011189:Potassium Chloride; D011817:Rabbits; D012433:Ryanodine / Q000494:pharmacology / Q000627:therapeutic use*; D012965:Sodium Chloride; D016277:Ventricular Function, Left / Q000187:drug effects
D001639:Bicarbonates; D002314:Cardioplegic Solutions; C041711:St. Thomas' Hospital cardioplegic solution; D012433:Ryanodine; D012965:Sodium Chloride; D011189:Potassium Chloride; D003402:Creatine Kinase; D004110:Diltiazem; D008274:Magnesium; D002122:Calcium Chloride